Emcure Pharma shares rise 7% after Q2 profit jumps 29 per cent
The pharmaceutical company reported an adjusted profit after tax of Rs 325.1 crore for the second quarter of FY27.
Shares of Emcure Pharmaceuticals rose as much as 7.3 per cent to hit an intraday high of Rs 2,021 apiece on the NSE on Tuesday, November 3, according to The Economic Times. The stock price increase followed the company's report of a 29.3 per cent year-on-year increase in adjusted profit after tax (PAT) for the second quarter of FY27.
The company's adjusted PAT rose to Rs 325.1 crore in Q2FY27, up from Rs 251.4 crore in the same quarter of the previous financial year. Revenue from operations increased 24.3 per cent year-on-year to Rs 2,820.5 crore, compared to Rs 2,269.8 crore in Q2FY26.
Earnings before interest, taxes, depreciation and amortisation (EBITDA) rose 30.9 per cent year-on-year to Rs 574.8 crore. The EBITDA margin improved by 103 basis points to 20.4 per cent from 19.3 per cent in the year-ago quarter.
Domestic revenue grew 12 per cent year-on-year to Rs 1,155.3 crore, led by the women's health, cardio-metabolics and central nervous system segments. International revenue grew 34.5 per cent year-on-year to Rs 1,665.2 crore during the quarter.
As part of its One Emcure vision, the company plans to merge Zuventus and Emcutix with the holding company. This move is intended to simplify the group's holding structure and achieve synergies across corporate functions and backend operations.